Relacorilant Plus Nab-Paclitaxel Approved for Platinum-Resistant Ovarian Cancer

Originally published by our sister publication Clinical Oncology NewsBy Jennifer KulpaThe FDA has approved the selective glucocorticoid receptor antagonist relacorilant (Lifyorli, Corcept) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic regimens, including bevacizumab.Adobe Stock Art.The efficacy and safety of this regimen were demonstrated in the phase 3 ROSELLA trial (Clinic